Compounds > xanthenone-4-acetic acid
Page last updated: 2024-12-08

xanthenone-4-acetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

xanthenone-4-acetic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161881
CHEMBL ID28715
SCHEMBL ID107952
MeSH IDM0181588

Synonyms (15)

Synonym
9h-xanthene-4-acetic acid, 9-oxo-
xaa ,
xanthanone-acetic acid
nsc677590
2-(9-oxoxanthen-4-yl)acetic acid
NCI60_027674
CHEMBL28715
35614-21-2
xoaa
xanthenone-4-acetic acid
SCHEMBL107952
DTXSID60189087
xanthenone acetic acid
2-(9-oxo-9h-xanthen-4-yl)acetic acid
2-(9-oxo-9h-xanthen-4-yl)aceticacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID154743Inhibition of 10e6 P388 leukemic cells in mice, intraperitoneal administration1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
AID127211Antitumor activity against the subcutaneously implanted C38 colon tumor in mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
AID111666Ability to cause early haemorrhagic necrosis of colon 38 tumors in mice.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
AID119961Optimal dose to achieve the level of activity cited in colon 38 tumors after intraperitoneal administration in mice.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
AID201894Ability of compound (220 mg/kg, q7dx2) to inhibit growth of Sc colon 38 tumor cells in mice1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
AID43494Optimal dose 24 hr after intraperitoneal administration against C38 colon tumor cells in mice.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids.
AID43485In Vivo antitumor effect on subcutaneously implanted C38 colon tumor in mice and examined by histopathology and compared with control.( ++ = >90% hemorrhagic necrosis response) at optimal dose of 220 (mg/kg)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid.
AID20523Relative measure of lipophilicity was determined by using 4'-(9-acridinylamino)-methanesulfonanilide as internal standard1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
AID201899Inhibition of colon adenocarcinoma C38 tumor growth in mice, intraperitoneal administration1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
AID43490Percent necrosis activity against subcutaneous C38 colon tumor cells in vivo1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids.
AID133480Minimum dose required when administered intraperitoneally in mice as the sodium salt in water in a single dose. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
AID201890Activity against colon adenocarcinoma C38 tumor in mice, after intraperitoneal administration at optimal dose1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
AID154734The average percentage increase in the lifespan of P388 leukemic mice, when compound was administered intraperitoneally; NA means not active1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.76)18.7374
1990's18 (85.71)18.2507
2000's1 (4.76)29.6817
2010's1 (4.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.73 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nitrates
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.		2.8940monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
nitric acid
Nitric Acid: Nitric acid (HNO3). A colorless liquid that is used in the manufacture of inorganic and organic nitrates and nitro compounds for fertilizers, dye intermediates, explosives, and many different organic chemicals. Continued exposure to vapor may cause chronic bronchitis; chemical pneumonitis may occur. (From Merck Index, 11th ed). nitric acid : A nitrogen oxoacid of formula HNO3 in which the nitrogen atom is bonded to a hydroxy group and by equivalent bonds to the remaining two oxygen atoms.		1.9710nitrogen oxoacidprotic solvent;
reagent
nitrites
Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)		2.3820monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		1.9710nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		1.9710arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		4.18170xanthene
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		1.9810acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
flavone acetic acid
flavone acetic acid: structure given in first source		8.77110
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		3.2460monocarboxylic acid;
xanthones		antineoplastic agent
omega-n-methylarginine
omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.		1.9710amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
5-methylxanthen-9-one-4-acetic acid
5-methylxanthen-9-one-4-acetic acid: RN given refers to parent cpd; structure given in first source		3.0750
nitrogen dioxide
Nitrogen Dioxide: Nitrogen oxide (NO2). A highly poisonous gas. Exposure produces inflammation of lungs that may only cause slight pain or pass unnoticed, but resulting edema several days later may cause death. (From Merck, 11th ed) It is a major atmospheric pollutant that is able to absorb UV light that does not reach the earth's surface.		6.9810nitrogen oxide
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		03.92130
Colonic Neoplasms
Tumors or cancer of the COLON.		03.92130
Adenocarcinoma, Basal Cell
[description not available]		02.6730
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.6730
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.6730
Cancer of Kidney
[description not available]		01.9810
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		01.9810
Experimental Neoplasms
[description not available]		01.9810